Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

A Phase 1 Study Of Cmc-544 Administered As A Single Agent In Subjects With B-cell Non- Hodgkin's Lymphoma

To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

Inclusion Criteria:

• Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit
• At the expanded cohort, part 2 of the study, subjects must have one of the following:
• Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy
• Diffuse large B-cell lymphoma
• Age 18 years or older

Exclusion Criteria:

• Candidate for potentially curative therapies in the opinion of the investigator
• Chronic lymphocytic leukemia
• Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma